Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026

ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.

ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.